16.72
+2.2(+15.15%)
Currency In USD
| Previous Close | 14.52 |
| Open | 14.4 |
| Day High | 16.88 |
| Day Low | 14.4 |
| 52-Week High | 16.95 |
| 52-Week Low | 3.91 |
| Volume | 2.01M |
| Average Volume | 1.26M |
| Market Cap | 1.15B |
| PE | -5.57 |
| EPS | -3 |
| Moving Average 50 Days | 12.91 |
| Moving Average 200 Days | 9.63 |
| Change | 2.2 |
If you invested $1000 in EyePoint Pharmaceuticals, Inc. (EYPT) 10 years ago, it would be worth $441.16 as of December 05, 2025 at a share price of $16.72. Whereas If you bought $1000 worth of EyePoint Pharmaceuticals, Inc. (EYPT) shares 5 years ago, it would be worth $3,412.24 as of December 05, 2025 at a share price of $16.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
GlobeNewswire Inc.
Nov 19, 2025 12:00 PM GMT
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline 56-week data for LUGANO in mid-2
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today a
EyePoint Announces Pricing of Public Offering
GlobeNewswire Inc.
Oct 15, 2025 2:43 AM GMT
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today a